Fentanyl is indicated for the management of severe pain in patients who require continuous opioid analgesia.
Amarin has developed a Fentanyl TDS using its drug-in-adhesive technology. Fentanyl TDS is generic to Durogesic SMAT and is currently commercialized in Germany, France, Spain, Italy, Greece, Hungary, Taiwan, South Africa and Argentine under different brand names (Fentadolon®, Fentanyl Biogaran®, Dolforin®, Adco Tenyl®, Talnur®, Myfene®, etc.), in four strengths.
Presently, Fentanyl TDS concluded the Mutual Recognition Procedure in Europe and is approved in several countries of Latinamerica. Recently, two additional strengths have been approved in Germany.
Europe (1503743), Mexico (245834) and India (216861). Two International Patent Applications were filed in 2003 (PCT/GB2003/002118). In 2011 a patent was granted in USA (8017146).
Amarin is seeking to license this product for different territories of America, Europe and rest of the world.
Mr. Sergio Lucero
Amarin is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how.View profile
Clients in focus...